{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT02550873: Phase 2 Interventional Completed Idiopathic Pulmonary Fibrosis
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01015560: Phase 2 Interventional Completed Metastatic Cancer
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00295958: Phase 2 Interventional Completed Melanoma (Skin)
(2005)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02545504: Phase 3 Interventional Completed Gastric Adenocarcinoma
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02518620: Phase 2 Interventional Completed Rheumatoid Arthritis
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00037700: Phase 2 Interventional Completed Rheumatoid Arthritis
(2001)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:laprituximab emtansine [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:laprituximab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02239211: Phase 2 Interventional Completed Primary Sclerosing Cholangitis
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03117998: Phase 2 Interventional Completed Type1 Diabetes Mellitus
(2017)
Source URL:
Class:
PROTEIN
